BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2941263)

  • 1. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy.
    Zeiler HJ; Metzger KG; Schacht P; Grohe K
    Drugs Exp Clin Res; 1985; 11(5):343-50. PubMed ID: 2941263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo.
    Zeiler HJ; Voigt WH
    Am J Med; 1987 Apr; 82(4A):87-90. PubMed ID: 3107381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of piperacillin/quinolone combinations].
    Soussy CJ; Leclercq R; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):357-60. PubMed ID: 3136421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC; Smith JT
    Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
    Chalkley LJ; Koornhof HJ
    Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.
    Zeiler HJ; Beermann D; Wingender W; Förster D; Schacht P
    Infection; 1988; 16 Suppl 1():S19-23. PubMed ID: 3286510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative in vitro study of the activity of 5 quinolones against Acinetobacter calcoaceticus].
    Joly-Guillou ML; Bergogne-Berezin E
    Pathol Biol (Paris); 1985 May; 33(5):416-20. PubMed ID: 3162142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of ciprofloxacin on the ultrastructure of gram-negative and gram-positive bacteria.
    Voigt WH; Zeiler HJ
    Arzneimittelforschung; 1985; 35(10):1600-3. PubMed ID: 2934069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo action of mezlocillin and azlocillin combined with sisomicin.
    Dzierzanowska D; Jeljaszewicz J
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Sep; 255(2-3):346-55. PubMed ID: 6417945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro sensitivity at 18 antibiotics of 192 strains of Pseudomonas aeruginosa isolated at Garches Hospital].
    Ronco E; Vacheron F; Orabona A
    Pathol Biol (Paris); 1987 May; 35(5):558-62. PubMed ID: 3112708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I; Smith JT
    Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.